Sweden· SE-20150318000071
Praxbind 50 mg/ml Injektions-/infusionsvätska, lösning
A medicinal product containing idarucizumab, registered in Sweden by Boehringer Ingelheim International GmbH.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Idarucizumab
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20150318000071
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idarucizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumPraxbind 2.5 g/50 mlBoehringer Ingelheim International
- CzechiaPRAXBINDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainPRAXBIND 2.5 G/50 ML SOLUCION INYECTABLE Y PARA PERFUSIONBoehringer Ingelheim International Gmbh
- FinlandPraxbindBoehringer Ingelheim International GmbH
- IrelandPraxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim International GmbH
- IcelandPraxbindBoehringer Ingelheim International GmbH*
- NorwayPraxbindBoehringer Ingelheim International GmbH
- PolandPraxbindBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praxbind
- Liechtenstein · Praxbind
- Norway · Praxbind
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4093aad1-74ab-43d8-b875-43302777dfeb GET /v1/drugs/4093aad1-74ab-43d8-b875-43302777dfeb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EPAR",
"EMA"
],
"se_npl_id": "20150318000071",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20150318000071",
"product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/praxbind-epar-product-information_sv.pdf"
}See everything about idarucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.